---
title: PDP1 is a key metabolic gatekeeper and modulator of drug resistance in FLT3-ITD-positive
  acute myeloid leukemia
date: '2023-11-07'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37935978/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20231108170854&v=2.17.9.post6+86293ac
source: heidelberg[Affiliation]
description: High metabolic flexibility is pivotal for the persistence and therapy
  resistance of acute myeloid leukemia (AML). In 20-30% of AML patients, activating
  mutations of FLT3, specifically FLT3-ITD, are key therapeutic targets. Here, we
  investigated the influence of FLT3-ITD on AML metabolism. Nuclear Magnetic Resonance
  (NMR) profiling showed enhanced reshuffling of pyruvate towards the tricarboxylic
  acid (TCA) cycle, suggesting an increased activity of the pyruvate dehydrogenase
  complex ...
disable_comments: true
---
High metabolic flexibility is pivotal for the persistence and therapy resistance of acute myeloid leukemia (AML). In 20-30% of AML patients, activating mutations of FLT3, specifically FLT3-ITD, are key therapeutic targets. Here, we investigated the influence of FLT3-ITD on AML metabolism. Nuclear Magnetic Resonance (NMR) profiling showed enhanced reshuffling of pyruvate towards the tricarboxylic acid (TCA) cycle, suggesting an increased activity of the pyruvate dehydrogenase complex ...